Evidence for disruption of sphingolipid metabolism in schizophrenia

Journal of Neuroscience Research

Volumn 87, Issue 1, 2009, Pages 278-288

  Narayan, Sujatha ^a   Head, Steven R ^a   Gilmartin, Timothy J ^a   Dean, Brian ^b,c,d   Thomas, Elizabeth A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Gene expression glycolipid; Glycosylation; Microarray; Schizophrenia

Indexed keywords

CARBOHYDRATE BINDING PROTEIN; CELL ADHESION MOLECULE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; GALACTOSE 3 O SULFOTRANSFERASE 1; GALACTOSYLCERAMIDASE; GALACTOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 8; GLYCAN; GLYCOSPHINGOLIPID; GLYCOSYLTRANSFERASE; HALOPERIDOL; HYDROLASE; N ACYLSPHINGOSINE AMINOHYDROLASE 1; PHOSPHATASE; PIMOZIDE; PROTEIN B4GALT6; PROTEOGLYCAN; REMOXIPRIDE; RISPERIDONE; SERINE PALMITOYLTRANSFERASE; SERINE PALMITOYLTRANSFERASE LONG CHAIN BASE SUBUNIT 2; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE PHOSPHATASE 1; SULFOTRANSFERASE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GLYCOBIOLOGY; HUMAN; HUMAN TISSUE; LIPID METABOLISM; MALE; MYELINATION; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LINEAR MODELS; LIPID METABOLISM DISORDERS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREFRONTAL CORTEX; SCHIZOPHRENIA; SPHINGOLIPIDS; YOUNG ADULT;

EID: 63049120234     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21822     Document Type: Article

References (48)

1. Abi-Dargham A, Laruelle M, Lipska B, Jaskiw GE, Wong DT, Robertson DW, Weinberger DR, Kleinman JE. 1993. Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdala. Brain Res 616:53-57.
2. Aston C, Jiang L, Sokolov BP. 2005. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 10:309-322.
3. Axford J. 2001. The impact of glycobiology on medicine. Trends Immunol 22:237-239.
4. Benes FM, Matzilevich D, Burke RE, Walsh J. 2006. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 11:241-251.
5. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Statist Soc B 57:289-300.
6. Bezchlibnyk-Butler K, Jeffries JE. 1999. Clinical handbook of psychotropic drugs. Toronto: Hogrefe & Huber Publishers.
7. Boggs JM, Gao W, Hirahara Y. 2008. Myelin glycosphingolipids, galactosylceramide and sulfatide, participate in carbohydrate-carbohydrate interactions between apposed membranes and may form glycosynapses between oligodendrocyte and/or myelin membranes. Biochim Biophys Acta 1780:445-455.
8. Brunngraber EG, Davis LG, Rieser C, Reddy MV. 1981. Urinary glycoconjugates in schizophrenic patients. Biol Psychiatry 16:741-751.
9. Cherayil GD. 1969. Estimation of glycolipids in four selected lobes of human brain in neurological diseases. J Neurochem 16:913-920.
10. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60:443-456.
11. Dean B, Keriakous D, Scarr E, Thomas EA. 2007. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Aust NZ J Psychiatry 41:308-320.
12. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA. 2006. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96:743-757.
13. Desplats PA, Denny CA, Kass KE, Gilmartin T, Head SR, Sutcliffe JG, Seyfried T, Thomas EA. 2007. Glycolipid and ganglioside metabolism imbalances In Huntington's disease. Neurobiol Dis (in press).
14. Fishburn CS, Elazar Z, Fuchs S. 1995. Differential glycosylation and intracellular trafficking for the long and short isoforms of the D2 dopamine receptor. J Biol Chem 270:29819-29824.
15. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T. 2005. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 7:1118-1123.
16. Hannun YA. 1994. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269:3125-3128.
17. Harrington KA, Augood SJ, Faull RL, McKenna PJ, Emson PC. 1995. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study. Brain Res Mol Brain Res 33:333-342.
18. Harrison PJ. 1999. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593-624.
19. Haselhorst U, Schenk H, Beyer I, Uebelhack R, Franke E, Kielstein V. 1988. Abnormality of gangliosides in erythrocyte membranes of schizophrenic patients. Clin Physiol Biochem 6:281-284.
20. Hill C, Keks NA, Roberts S, Opeskin K, Dean B, Copolov DL. 1996. Postmortem brain studies in schizophrenia: The problems of diagnosis. Am J Psychiatry 153:533-537.
21. Katsel P, Li C, Haroutunian V. 2007. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 32:845-856.
22. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, Lees AJ, Marsden CD. 1995. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 28:311-318.
23. Kolter T, Sandhoff K. 2006. Sphingolipid metabolism diseases. Biochim Biophys Acta 1758:2057-2079.
24. Kubicki M, McCarley RW, Shenton ME. 2005. Evidence for white matter abnormalities in schizophrenia. Curr Opin Psychiatry 18:121-134.
25. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmam M, Wang C, Kobayashi M, Horton H, Brown EL. 1996. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680.
26. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. 1997. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry 54:1089-1095.
27. Narayan S, Tang B, Head SR, Gilmartin TJ, Dean B, Sutcliffe JG, Thomas EA. 2008. Gene expression differences in schizophrenia at early, intermediate and late stages of illness. In preparation.
28. Navon R. 1991. Molecular and clinical heterogeneity of adult GM2 gangliosidosis. Dev Neurosci 13:295-298.
29. Nawa H, Takei N. 2006. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 56:2-13.
30. Norton WT. 1977. Isolation and characterization of myelin. In: Morell P, editor. New York: Plenum Press. p 161-199.
31. Quirk PL, Rao S, Roth BL, Siegel RE. 2004. Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells. J Neurosci Res 77:498-506.
32. Radmacher MD, McShane LM, Simon R. 2002. A paradigm for class prediction using gene expression profiles. J Comput Biol 9:505-511.
33. Rapoport JL, Addington AM, Frangou S, Psych MR. 2005. The neuro-developmental model of schizophrenia: update 2005. Mol Psychiatry 10:434-449.
34. Rosebush PI, MacQueen GM, Clarke JT, Callahan JW, Strasberg PM, Mazurek MF. 1995. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry 56:347-353.
35. Rutishauser U. 2008. Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat Rev Neurosci 9:26-35.
36. Ruvolo PP. 2003. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47:383-392.
37. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. 2007. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46.
38. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz WF. 2004. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 56:41-45.
39. Sequeira A, Turecki G. 2006. Genome wide gene expression studies in mood disorders. Omics 10:444-454.
40. Svennerholm L. 1964. The gangliosides. J Lipid Res 5:145-155.
41. Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J. 2005. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem 280:28110-28117.
42. Thompson JL, Pogue-Geile MF, Grace AA. 2004. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr Bull 30:875-900.
43. van Heyningen W. 1974. Gangliosides as membrane receptors for tetanus toxin, cholera toxin and serotonin. Nature 249:415-417.
44. Woo TU, Crowell AL. 2005. Targeting synapses and myelin in the prevention of schizophrenia. Schizophr Res 73:193-207.
45. Yamaguchi Y. 2002. Glycobiology of the synapse: the role of glycans in the formation, maturation, and modulation of synapses. Biochim Biophys Acta 1573:369-376.
46. Yu RK, Bieberich E, Xia T, Zeng G. 2004. Regulation of ganglioside biosynthesis in the nervous system. J Lipid Res 45:783-793.
47. Zelnik N, Khazanov V, Sheinkman A, Karpati AM, Peleg L. 2000. Clinical manifestations of psychiatric patients who are carriers of tay-sachs disease. Possible role of psychotropic drugs. Neuropsychobiology 41:127-131.
48. Zhang X, Ding L, Sandford AJ. 2005. Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. BMC Mol Biol 6:4.